Internal medicine

Oncology Expert, Dr. Nathan Pennell of the Cleveland Clinic Taussig Cancer Institute, Joins Vial's Oncology CRO Advisory Board

Retrieved on: 
Tuesday, November 1, 2022
Brigham and Women's Hospital, MD, Gastroenterology, Publication, EPRO, Dana–Farber Cancer Institute, CRO, Vial, Clinical research, EDC, Efficiency, Case Comprehensive Cancer Center, Cancer, Dermatology, Ophthalmology, Oncology, Journal of Oncology Practice, JAMA Oncology, College of Medicine, Digital technology, Hospital, Technology, Neurology, University, Doctor of Philosophy, Internal medicine, ESourcing Capability Model, Journal, Patient, Dana, Multimedia, Lung cancer, SAN, Fine chemical, Medical imaging, Pharmaceutical industry, Neuroscience, Medicine

SAN FRANCISCO, Nov. 1, 2022 /PRNewswire/ -- Dr. Nathan Pennell of the Cleveland Clinic Taussig Cancer Institute has joined Vial's Oncology CRO Advisory Board.

Key Points: 
  • SAN FRANCISCO, Nov. 1, 2022 /PRNewswire/ -- Dr. Nathan Pennell of the Cleveland Clinic Taussig Cancer Institute has joined Vial's Oncology CRO Advisory Board.
  • Nathan Pennell, MD, Ph.D., FASCO, is a Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute.
  • I am delighted to serve as an advisor for their Oncology CRO with the goal of helping cancer patients receive treatments sooner," said Dr. Pennell on joining Vial's scientific advisory board.
  • Vial operates across multiple therapeutic areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , and Neurology CRO ).

Tampa General Hospital is the First U.S. Emergency Department to Offer Rapid Blood Test for Concussion and Traumatic Brain Injury to Patients

Retrieved on: 
Tuesday, November 1, 2022
Skull, Bruise, Plasma, Wilson, Brain, Tampa General Hospital, Health, Sports medicine, Risk assessment, Patient, Concussion, Blood, Student, Department, Traumatic brain injury, Abbott, Physician, CT, Internal medicine, Protein, Physical examination, FDA, Radiation, Accident, Brain damage, TBI, Falls, Diagnosis, Medical imaging, Health insurance, Family

TAMPA, Fla., Nov. 1, 2022 /PRNewswire/ -- Physicians at Tampa General Hospital's emergency department are the first in the nation, outside of a clinical trial setting, to use an FDA-cleared rapid blood test to successfully evaluate patients who are 18 and older with mild traumatic brain injury (TBI), including concussions. Results are available in approximately 15 minutes.

Key Points: 
  • TAMPA, Fla., Nov. 1, 2022 /PRNewswire/ -- Physicians at Tampa General Hospital's emergency department are the first in the nation, outside of a clinical trial setting, to use an FDA-cleared rapid blood test to successfully evaluate patients who are 18 and older with mild traumatic brain injury (TBI), including concussions.
  • "It provides definitive data as we work to confirm a concussion or a traumatic brain injury.''
  • Here's how the test works:
    This test measures specific proteins present in the blood after a traumatic brain injury, including concussion.
  • "Tampa General is the first emergency department to use this test method and make it available for patient use," said Michele Moran, senior nursing director in the Tampa General Emergency Department.

Houston Internist Thomas Lux, MD Now Offering Exclusive Support and Service Program from Concierge Choice Physicians

Retrieved on: 
Tuesday, November 1, 2022
Concierge medicine, MD, University, Internal medicine, Health, Sunset Boulevard, Time, CCP, Hospital, Physician, Program, Medicine, Communication, Patient, Multimedia, Pharmaceutical industry, Health insurance, Health care

ROCKVILLE CENTRE, N.Y., Nov. 1, 2022 /PRNewswire/ -- Concierge Choice Physicians (CCP), the nation's leading full-service concierge medical service provider, announces today that Thomas Lux, MD, internal medicine specialist with a practice in Houston, TX, is now offering patients the Concierge Choice, a full-practice membership medicine program that allows physicians and patients to spend more time together in a comprehensive, nurturing environment conducive to better health and wellness. 

Key Points: 
  • Dr. Lux is one of a growing number of physicians nationwide, and particularly in Houston, who offer concierge medicine.
  • "I want to be there for my patients, and deliver the kind of personal support that is getting increasingly complicated," said Dr. Lux.
  • For more information on the program, or to join, contact Concierge Choice Physicians at (877) 888-5590.
  • Dedicated to providing real options for patients and physicians, Concierge Choice Physicians is the largest private provider of the full range of concierge programs available todayHybrid and FullFlex.

Lung Cancer Research Foundation Welcomes Chief Scientific Officer

Retrieved on: 
Tuesday, November 1, 2022
SAB, MD, Yale school, Publication, Survival, UPMC Hillman Cancer Center, Mesothelioma, Doctor of Philosophy, Clinical research, Karmanos Cancer Institute, Thymoma, Organization, Division, Research, Society, Industry, Lung cancer, NCI, Yale School of Medicine, Pleasure, Diagnosis, American Lung Association, Wayne State University, University, Internal medicine, Associate, Leadership, FACP, 2021 Essex County Council election, Quality of life, UPMC, Pathology, American Society of Clinical Oncology, United States Air Force Scientific Advisory Board, Management, Medical imaging, SWOG, Medicine

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce the addition of Antoinette J. Wozniak, MD, FACP, FASCO to its senior leadership team as its first Chief Scientific Officer. She will begin her role in its official capacity in February 2023.

Key Points: 
  • NEW YORK, Nov. 1, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce the addition of Antoinette J. Wozniak, MD, FACP, FASCO to its senior leadership team as its first Chief Scientific Officer.
  • Her clinical research focus has been in lung cancer, mesothelioma, and thymus gland cancer, and has authored more than 200 publications and abstracts.
  • The Lung Cancer Research Foundation (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer.
  • LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.

NOV 2: NEW Hepatology Research Unveiled during Virtual Press Pre-Brief for The Liver Meeting®

Retrieved on: 
Monday, October 31, 2022
Infectious Diseases, General Health, Health, COVID-19, Yee, Division, TLM, American Association, Hepatitis, Massachusetts General Hospital, American Association for the Study of Liver Diseases, Cedars-Sinai Medical Center, Bariatric surgery, AASLD, Association, Program, Patient, 2021 Essex County Council election, Yale School of Medicine, NASH, Mortality, Disease, Clinical trial, University of California, Internal medicine, University, NAFLD, Liver disease, Public health, Cirrhosis, NEW, COVID, COVID-19, Liver, Department, Pharmaceutical industry, Dietary supplement, D.C

To highlight newest cutting-edge research on liver disease, the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting (TLM) will hold a virtual news conference Wednesday, November 2 at 12noon Eastern.

Key Points: 
  • To highlight newest cutting-edge research on liver disease, the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting (TLM) will hold a virtual news conference Wednesday, November 2 at 12noon Eastern.
  • IMPACT OF THE COVID-19 PANDEMIC ON MORTALITY RATE OF LIVER DISEASE IN THE UNITED STATES: A POPULATION-BASED STUDY, 2010-2021.
  • The American Association for the Study of Liver Disease holds The Liver Meeting for 10,000 attendees to obtain data on the newest cutting-edge scientific research on hepatology.
  • Journalists may confirm participation in the virtual sneak peek by registering for Zoom meeting at: https://us02web.zoom.us/j/85153846101?pwd=ZXZ4Y3JUYVdMbzhydW5nd0IwVXp5dz09 .

Specialdocs Reports Significantly Increased Demand for Subspecialty Concierge Medicine Practices

Retrieved on: 
Monday, October 31, 2022
Health, Tremor, Consultant, Internal, Bauer, Multimedia, Time, Rheumatology, Concierge, Physician, DO, Alternative medicine, MD, Research, Diabetes, Endocrinology, Degenerative disease, Family, Parkinson's disease, Patient, Cardiology, Dystonia, Pediatrics, Alternative, Doctor of Philosophy, Internal medicine, Growth, Concierge medicine, Empathy, Quality of life, Neurology, Goal, Movement, Environment, Education, Movement disorders, Medicine, Pharmaceutical industry

CHICAGO, Oct. 31, 2022 /PRNewswire/ -- The benefits of delivering remarkably personalized patient care in a concierge, or membership, medicine practice are in high demand among physicians in prominent subspecialties, according to Specialdocs Consultants CEO Terry Bauer.

Key Points: 
  • "While initially rooted in family and internal medicine, the tenets of a concierge practice are compelling for any physician seeking to establish a powerful connection with their patients and provide individualized, longitudinal care."
  • Rena Ahuja, MD , concierge Internal and Integrative Medicine physician: "I take time to incorporate each patient's mental, emotional and spiritual framework along with the physical aspects of their ailments.
  • Thankfully, I chose to look into concierge medicine, a model that has proven to be a tremendous fit at this point in my career.
  • Concierge medicine pioneer Specialdocs is celebrating two decades of transforming physicians' professional lives, empowering them to deliver highly personalized patient care.

DM Clinical Research Honored for Excellence in Patient Centricity

Retrieved on: 
Monday, October 31, 2022
Sanofi, View, Multimedia, Time, Performance, Confusion, Physician, Ron Link (patient advocate), Arham, Gastroenterology, GIPS, Society, Patient, Congress, Pediatrics, Marketing, Psychiatry, Clinical trial, SCRS, Internal medicine, Medicine, Communication, DM, KPI-driven code analysis, Patient satisfaction, Vaccine, Health, Pharmaceutical industry, Medical imaging

HOUSTON, Oct. 31, 2022 /PRNewswire/ -- DM Clinical Research, a national network of clinical trial sites, has earned the Society for Clinical Research Sites (SCRS) 2022 Excellence in Patient Centricity Award.

Key Points: 
  • HOUSTON, Oct. 31, 2022 /PRNewswire/ -- DM Clinical Research , a national network of clinical trial sites, has earned the Society for Clinical Research Sites (SCRS) 2022 Excellence in Patient Centricity Award.
  • "At DM Clinical Research our belief has always been to create systems and processes that are patient-centric and ensure that our core values are not just talked about, but operationalized through measurable outcomes," said Hera Arham, Director of Marketing and Patient Engagement at DM Clinical Research.
  • SCRS applauds DM Clinical Research for their industry-leading initiatives that have improved the patient journey from start to finish.
  • DM Clinical has become a national leader in clinical research and has received industry recognition from the World Vaccine Congress as highly commended for Best Clinical Trial Site.

FTC Takes Second Action Against JAB Consumer Partners to Protect Pet Owners from Private Equity Firm’s Rollup of Veterinary Services Clinics

Retrieved on: 
Monday, October 31, 2022
Commission, Jimmy Gobble, Washington Metro, Internal medicine, Federal, Anesthesiology, Social media, FTC, Washington metropolitan area, JAB, Federal Trade Commission, Regulations.gov, Acquisition, Blog, Complaint, Compliance, Oncology, Federal Register, Bureau, Competition, Processor register, Sale, NVA, Cardiology, Critical care, Radiology, News, Neurology, Growth, Ophthalmology, Dermatology, LLC, Veterinary medicine, Veritas, Ethos
Key Points: 

FTC Approves Final Order Protecting Pet Owners from Private Equity Firm’s Anticompetitive Acquisition of Veterinary Services Clinics

Retrieved on: 
Monday, October 31, 2022
Commission, Internal medicine, Social media, Federal Trade Commission, JAB, Acquisition, Blog, Complaint, Oncology, Critical care, News, Neurology, Ophthalmology, FTC, LLC, Veterinary medicine, Concord

Private equity firm JAB is the parent of two companies that operate chains of veterinary clinics providing general, specialty, and emergency care Compassion-First Pet Hospitals and National Veterinary Associates, Inc.

Key Points: 
  • Private equity firm JAB is the parent of two companies that operate chains of veterinary clinics providing general, specialty, and emergency care Compassion-First Pet Hospitals and National Veterinary Associates, Inc.
  • Under the terms of the final settlement, the Commission imposed robust prior approval and prior notice requirements on JABs future acquisitions of specialty and emergency veterinary clinics.
  • - In and around San Francisco, California, for internal medicine, neurology, ophthalmology, and surgery veterinary specialty services, as well as emergency veterinary services would be harmed.
  • - In and between Oakland, Berkeley, and Concord, California, for internal medicine, medical oncology, and surgery veterinary specialty services, as well as emergency veterinary services would be harmed.

LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022

Retrieved on: 
Friday, October 28, 2022
MBBS, Therapy, Seminal vesicles, Company, Hubli railway division, Institute of Liver and Biliary Sciences, AASLD, Fibrosis, Safety, Disease, Internal medicine, Liver disease, Inflammation, Hepatology, PSC, Department, Neurodegeneration, LMT, Division, Program, Patient, Association, Technology, American Association for the Study of Liver Diseases, Cirrhosis, Degenerative disease, American Association, Research, Mayo Clinic, Liver, Steatosis, NASH, Exosome, EVS, Population, Lists of diseases, Primary sclerosing cholangitis, Time, Dietary supplement, Pharmaceutical industry, Gastroenterology

SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.

Key Points: 
  • As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.
  • Oral Presentation Date and Time: Monday, November 7, 2022, 4:30 PM
    AASLD is the leading global association in the liver disease field founded in 1950.
  • AASLD The Liver Meeting is an annual event in which more than 10,000 attendees - hepatologists, health professionals, and pharmaceutical industry - participate from around the world.
  • LISCure's new drug, a clinical-stage novel strain candidate, aims the "first-in-class" microbiome-based therapy for NASH and other liver diseases.